Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

2016 ASCO Annual Meeting

Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes (French Language)

Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses in French patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506).

To see the English language version of this video, please click here.

Lung Cancer

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

Vali A. Papadimitrakopoulou, MD, of MD Anderson Cancer Center, and Gideon Michael Blumenthal, MD, of the US Food and Drug Administration, discuss milestone analyses with immune checkpoint inhibitors, targeted therapy, and standard therapy in metastatic non–small cell lung cancer trials submitted to the FDA (Abstract 9010).

Pancreatic Cancer

John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial

John P. Neoptolemos, MD, PhD, of the University of Liverpool, discusses findings from this international phase III study of adjuvant combination chemotherapy: gemcitabine and capecitabine vs monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma (Abstract LBA4006).

CNS Cancers

James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients

James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in older patients with this tumor (Abstract LBA2).

Leukemia

Lymphoma

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).

Apr

Today In Oncology

Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting

Related Videos

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes (French Language)

Vali A. Papadimitrakopoulou, MD, and Gideon Michael Blumenthal, MD, on NSCLC: An Updated Pooled Analysis

John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial

James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients

Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?

Financial Hardship and Late-Stage Cancer Diagnosis

Agent Orange Exposure Linked to MDS Risk and Progression

One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia

Low-Risk Endometrial Cancer Does a Lack of Adjuvant Therapy Affect Survival

ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence